Usage of the Human Protein Atlas (HPA) database to examine INHA protein levels in lung carcinoma
April 2022 (Cheeloo College of Medicine, Qilu Hospital of Shandong University, Shandong University, 107 Wenhua Xi Road, Jinan 250012, China)
INHA: a novel potential diagnostic indicator for lung carcinoma (LUAD).
Inhibin A (INHA) is upregulated in various human cancers such as high-grade prostate, ovarian, adrenal, gastric, and pancreatic tumors, colon cancer and melanoma. Although INHA expression correlates with the development, growth, and progression of multiple cancer types, its biological role in lung adenocarcinoma patients is yet unclear.
A new study published in Translational Oncology (2023) uses the Human Protein Atlas (HPA) database to examine INHA protein levels in lung carcinoma. The findings reveal a significantly higher INHA protein level in lung carcinoma compared to normal tissues.
The overexpression of INHA in lung carcinoma is linked to a poor prognosis, thus demonstrating its potential as an immunotherapeutic and predictive biomarker in lung adenocarcinoma.
Read the full article here: https://lnkd.in/diYzRigU
👉 Anti-INHA polyclonal (HPA019141)